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Abstract
Background: Cancers are some of the leading causes of human deaths worldwide and their relative importance
continues to increase. Since an increasing proportion of cancer patients are acquiring resistance to traditional
chemotherapeutic agents, it is necessary to search for new compounds that provide suitable specific
antiproliferative affects that can be developed as anticancer agents. Propolis from the stingless bee, Trigona
laeviceps, is one potential interesting source that is widely available and cultivatable (as bee hives) in Thailand.
Methods: Propolis (90 g) was initially extracted by 95% (v/v) ethanol and then solvent partitioned by sequential
extractions of the crude ethanolic extract with 40% (v/v) MeOH, CH2Cl2 and hexane. After solvent removal by
evaporation, each extract was solvated in DMSO and assayed for antiproliferative activity against five cancer
(Chago, KATO-III, SW620, BT474 and Hep-G2) and two normal (HS27 fibroblast and CH-liver) cell lines using the MTT
assay. The cell viability (%) and IC50 values were calculated.
Results: The hexane extract provided the highest in vitro antiproliferative activity against the five tested cancer cell
lines and the lowest cytotoxicity against the two normal cell lines. Further fractionation of the hexane fraction by
quick column chromatography using eight solvents of increasing polarity for elution revealed the two fractions
eluted with 30% and 100% (v/v) CH2Cl2 in hexane (30DCM and 100DCM, respectively) had a higher anti-
proliferative activity. Further fractionation by size exclusion chromatography lead to four fractions for each of
30DCM and 100DCM, with the highest antiproliferative activity on cancer but not normal cell lines being observed
in fraction# 3 of 30DCM (IC50 value of 4.09 - 14.7 μg/ml).
Conclusions: T. laeviceps propolis was found to contain compound(s) with antiproliferative activity in vitro on
cancer but not normal cell lines in tissue culture. The more enriched propolis fractions typically revealed a higher
antiproliferative activity (lower IC50 value). Overall, propolis from Thailand may have the potential to serve as a
template for future anticancer-drug development.
Background
Cancers are some of the major fatal diseases to humans.
Chemotherapy is one of the most widely used
approaches for the treatment of many cancers, but the
long-term use of chemotherapy can lead to drug resis-
tance via several different mechanisms, such as gene
mutation, DNA methylation and histone modification.
These resistance mechanisms have been reported to
play important roles in the resistance of cancers to
chemotherapeutic agents [1]. Thus, patients are gradu-
ally developing resistance to widely used and standard
chemotherapeutic agents, such as 5-fluorouracil, taxol,
doxorubicin, cisplatin, campothecin, paclitaxel and topo-
tecan [2]. Due to this resistance to cancer drugs, it is
important to find new anticancer agents in order that
they can be developed into novel anticancer drugs that
can circumvent the existing resistance mechanisms.
Herbs and other natural plant products have become
interesting sources for this purpose, but animal modified
or selected plant products have been largely overlooked.
Propolis, one of the economic natural products from
bees, is an interesting source for several bioactivities,
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such as antimicrobial as well as anti-cancer. Although
an animal product it is largely plant based in its chemi-
cal origins. It is a sticky resin and varies in colour,
including brown, green and red amongst others, based
upon the plant exudates that the bees have selectively
collected from flower buds, leaf buds and tree barks.
These plant resins are mixed with waxes and other bee
excretions, including enzymes [3], to form the final pro-
polis product. Although used as a sealing wax for filling
cracks and repairing combs, and in some cases embalm-
ing wax, the principal use of propolis in the beehive is
as a protective barrier against their enemies [4]. As such
it has broad antimicrobial activities and has been exten-
sively used in the traditional medicine [5]. In Europe,
propolis was accepted as an official drug due to its anti-
bacterial activity during the last 400 years [6]. Further-
more, propolis has been long used as a dietary
supplement for disease prevention [7], since it can pro-
vide antimicrobial activity, including antiviral activity
[8], anti-inflammatory [9], immunomodulatory [10],
antitumor [11] and antioxidant effects [12].
The chemical composition of each type of propolis
and its associated bioactivities mainly depend on the
macro- and micro-geographical regions, due to the dif-
ferences in the plant resin compositions or available
plant species [8,13], and on the bee species, due to the
different preference for food and resin plants and fora-
ging distances between bee species [14]. For example,
the pollen in the propolis from Apis mellifera in the
Preveza region of Northwest Greece was mainly from
Pinaceae [14] whilst in the propolis in Brazil it was
mainly from two poplar trees, Hyptis di Varicata and
Baccharis dracunculifolia [15,16], suggesting quiet dif-
ferent sources of plant resins and volatiles for the pro-
polis production. In addition, the propolis from A.
mellifera in Brazil, Chili and Myanmar presented a dif-
ferent in vitro cytotoxicity activity against the PANC-1
human pancreatic cancer cells in a nutrient-deprived
medium [16-18].
Although propolis is typically a complex mixture of
diverse compounds from plant resins, volatiles, pollen
and animal enzymes, etc, numbering over 300 character-
ized components, the reported bioactivities associated
with propolis have been found in both the crude and
the purified extracts [12,19], suggesting that they may
be associated with single compounds rather than com-
plex interactions between compounds, and so amenable
to purification. To date, most of the active compounds
from purified extracts have been found to be phenolics
and polyphenolics [20]. Propolin A and propolin B,
which belong to the prenylflavanone group, were the
main chemical components that could be isolated using
Nuclear Magnetic Resonance (NMR) from Taiwanese
propolis [21]. Both components displayed an in vitro
antiproliferative effect on human melanoma, C6 glioma
and HL-60 cell lines in tissue culture.
Caffeic acid phenethyl ester (CAPE), the main compo-
nent from A. mellifera propolis in Chili, along with a
considerable number of flavonoid compounds, such as
p-cumaric acid and ferulic acid, were purified and found
to display an in vitro antiproliferative effect on the KB,
DU-145 and Caco-2 cell lines in tissue culture [12].
Given that the main active components found to date
are plant derived flavonoids, it would seem likely to be
better to preserve the polyphenolic fraction of propolis
after purification.
Propolis from the stingless bee Trigona laeviceps
Smith (Hymenoptera: Apoidae) was used in this
research since these bees can be commercially culti-
vated in a sustainable and potentially ecologically
friendly manner in artificial hives (with the potential
add on value of certain crop plant pollination), and
can provide a lot of propolis per hive. In addition, the
bees are widely distributed throughout Thailand.
Although Umthong et al. reported that a high cyto-
toxicity on the SW620 colon cancer cell line was
obtained from the crude extract of propolis harvested
from T. laeviceps in Thailand [22], it is not recom-
mended to use or consume propolis in the form of a
crude extract because it may still contain various
adverse bioactivities. In this research, we attempted to
purify the ethanol crude extract of T. laeviceps propo-
lis from Samut Songkram, central Thailand, using a
bioassay-guided isolation procedure. Solvent partition-
ing of the propolis, based upon solvent polarity, was
performed and human cell lines derived from five dif-
ferent types of tissue cancers were used to screen for
any in vitro antiproliferative affect in comparison to
the two normal cell lines.
Methods
Sample collection
Propolis of T. laeviceps was collected from an apiary in
the Samut Songkram province, central Thailand, and
was kept in the dark at 4°C until use.
Ethanol crude extraction
The method of propolis extraction followed that
reported by Najafi et al. [23]. Briefly, propolis (90 g) was
cut into small pieces and was then extracted by 95% (v/
v) ethanol (400 ml) at 15°C with shaking at 100 rpm for
20 h. The suspension was then clarified of residual pro-
polis solid by centrifugation at 7,000 rpm for 15 min at
20°C. The supernatant was harvested and kept whilst
the pellet was re-extracted and then clarified as above
except using 100 ml and not 400 ml of 95% (v/v) etha-
nol. The two ethanolic extracts (supernatants) were
pooled together and evaporated in a rotary evaporator
Umthong et al. BMC Complementary and Alternative Medicine 2011, 11:37
http://www.biomedcentral.com/1472-6882/11/37
Page 2 of 8
(40°C). The obtained residue (crude ethanolic extract)
was weighed and stored at -20°C at dark.
Partial purification of the crude ethanolic extract of
propolis by solvent partitioning with different polarity
solvents
The ethanolic extract of the propolis was dissolved in
80% (v/v) methanol until it was not sticky and then an
equal volume of hexane was added, stirred (15 mins)
and then allowed to phase separate in a separating fun-
nel. The upper hexane phase containing the non-polar
compounds was harvested and kept whilst the 80% (v/v)
methanol phase containing polar compounds was
extracted three more times with hexane in the same
manner. The four hexane extracts were pooled, the sol-
vent evaporated in a rotary evaporator (40°C), and the
sticky liquid residue weighed to give the yield of the
hexane extract. The 80% (v/v) methanol phase was then
mixed with an equal volume of H2O to increase the par-
tition coefficient (solubility) of polar compounds, and
then extracted four times with an equal volume of
CH2Cl2 as per hexane above, except that following
phase separation the CH2Cl2 phase containing the less
polar compounds was the lower phase. The pooled
CH2Cl2 phases and the residual 40% (v/v) methanol
phase were separately evaporated to remove the respec-
tive solvent in a rotary evaporator (40°C), and the resi-
dues were each weighed to give the yield of the CH2Cl2
and methanolic extracts, respectively.
Chromatography
Quick column chromatography
Silica gel was packed into a glass funnel (50% of internal
volume) connected to a vacuum pump. The selected
fractions (see Bioassay guided selection below) were
mixed with CH2Cl2 until they were not sticky and were
then mixed with silica gel, evaporated to dryness and
loaded on top of the silica gel containing column. The
column was then eluted by various solvents (2,000 ml
each) of different polarities starting from the least polar
solvent and increasing, that is from 0:1, 1:9, 3:7, 1:1, 7:3
and 1:0 (v/v) of CH2Cl2: hexane and then followed by
5% and 10% (v/v) MeOH in CH2Cl2, respectively. A
reduced pressure was used in order to enable the flow
rate of the solvent through the column to be obtained,
and fractions were collected. Each fraction was solvent
evaporated in a rotary evaporator (40°C), and the resi-
due weighed before being dissolved in DMSO to the
required concentrations to assay for antiproliferative
activity as detailed below.
Size exclusion chromatography
Further partial purification of each selected fraction was
performed by size exclusion chromatography using a
Sephadex LH-20 column (10 ml internal volume). Each
selected fraction was dissolved in a 1:1 (v/v) ratio of
MeOH: CH2Cl2 until it was not sticky and was loaded
on top of the column. The column was then eluted with
10 ml of a 1:1 (v/v) ratio of MeOH: CH2Cl2, collecting 2
ml fractions. The four fractions obtained were then sol-
vent evaporated by a rotary evaporator (40°C), the resi-
due weighed and then dissolved in DMSO to the
required concentrations ready to assay for any selective
antiproliferation activity as detailed below.
Thin layer chromatography (TLC)
One-dimensional thin layer chromatography (TLC) was
used in order to group the obtained components and to
determine the purity of fractions. A silica gel plate (10
cm in height) was used as the stationary phase, and the
respective extracts or fractions were spotted at the start-
ing line at 0.5 - 1 cm intervals. The mobile phase sol-
vents used (one per TLC plate) were 1:0, 3:1 and 1:1 (v/
v) ratio of CH2Cl2: hexane. When the mobile phase had
almost reached the top of the plate, the samples were
visualized under U.V. light (254 nm). Alternatively, the
gel plate was sprayed by a 5% (v/v) H2SO4/0.03% (w/v)
a-naphtal methanolic solution, dried in an oven or hot
plate and visualized under U.V. light (350 nm).
Bioassay-guided isolation
Each of the three crude solvent partitioned extracts
(hexane, dichloromethane and methanolic) of propolis,
obtained as detailed above, were evaluated for their in
vitro antiproliferative activity on five selected cancer and
two normal cell lines in tissue culture using the MTT
assay as detailed below. The extract which provided the
best selective antiproliferative activity, that is the highest
activity on the cancer cell lines but not on the normal
cell lines, as determined by comparison of the IC50
values, was selected for further partial purification by
quick column silica chromatography. In the same way,
each fraction obtained from the quick column chroma-
tography was likewise assayed for selective antiprolifera-
tive activity on the cell lines and this was used to select
fractions for further size exclusion chromatography (see
above).
Cancer cell lines
The five selected cancer cell lines for screening for the
in vitro antiproliferative bioactivity were derived from
colon (SW620), breast (BT474), hepatic (Hep-G2), lung
(Chago), and stomach (Kato-III) tissue cancers. The two
normal cell lines used were of liver (CH-liver) and fibro-
blast (HS-27) origins and were used as comparative con-
trols to check for selective specificity towards cancer
cells rather than all dividing cells. All cell lines were cul-
tured in RPMI medium containing 5% (v/v) fetal calf
serum (complete medium) at 37°C in a humidified air
atmosphere containing 5% (v/v) CO2.
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MTT assay for proliferation
Cultured cells (5,000 cells) in 200 μl complete media
were transferred into each well of a flat 96 well plate
and then incubated at 37°C in a humidified air atmo-
sphere enriched with 5% (v/v) CO2 for 24 h in order to
let the cells attach to the bottom of each well. The cul-
tured cells were then treated with the tested propolis
extract (triplicate wells per condition) by the addition of
2 μl of serial dilutions of the propolis extract dissolved
in DMSO to give a final concentration of 100, 50, 25,
12.5, 6.25 and 3.125 μg/ml. In addition, 2 μl of DMSO
alone was added to another set of cells as the solvent
control. The cells were then cultured as above for
another 48 h prior to the addition of 10 μl of a 5 mg/ml
solution of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenylte-
trazolium bromide (MTT)into each well. The incubation
was continued for another 4 h before the media was
removed. A mixture of DMSO (150 μl) and glycine (25
μl) was added to each well and mixed to ensure cell
lysis and dissolving of the formasan crystals, before the
absorbance at 540 nm was measured. Three replications
of each experiment were performed and the half maxi-
mal inhibitory concentration (IC50) of each extract was
calculated as detailed below.
Half maximal inhibitory concentration (IC50)
The obtained absorbance at 540 nm was used to deter-
mine the percentage of cell survival assuming that 100%
survival was obtained from the solvent only control and
that no differences in metabolic activity existed between
surviving cells under the different conditions. Under
these assumptions, the percentage survival of the treated
cancer and normal cultured cells was calculated accord-
ing to the formula below:
Percentageofsurvival =
(Absorbanceoftreatedcells/Absorbanceofcontrol)× 100
The mean (± 1 standard deviation (SD)) cell survival
(%) was plotted against the corresponding propolis
extract concentration and the best fit line was used to
derive the estimated IC50 value from the concentration
that could provide a 50% cell survival.
Results
Antiproliferation of ethanol crude extract
From 90 g of T. laeviceps propolis a yield of 18 g (20%)
of crude ethanol extract was obtained as a sticky brown-
ish to dark brown resin with a distinctive smell. When
assayed in vitro on the five cancer and two normal cell
lines, using the MTT assay, the IC50 (μg/ml) values for
the five cancer cell lines ranged from 1.9-fold lower
(SW620 and BT474) to only 1.04-fold lower (Hep-G2)
than that for the control HS27 cell line (Table 1).
However, the CH-Liver control cell line was some 1.3-
fold more sensitive than the HS27 cell line and so only
three of the cancer cell lines showed reduced IC50 (μg/
ml) values compared to the control CH-liver cell line.
Over all, it indicates that the crude ethanolic extract of
T. laeviceps propolis contained some antiproliferative
activity, but with the overlapping variation within the
cancer and normal cell lines the existence of any selec-
tive specificity for cancer cells was less clear.
Active fractions after solvent partitioning of the crude
ethanolic propolis extract
After resolvation of the crude ethanolic extract in 80%
(v/v) methanol, sequential solvent partitioning with
three different polarity solvents was used to further frac-
tionate the propolis extracts. For each of the three sol-
vent extractions the new fractions obtained gave
different appearances (Table 2), but the CH2Cl2 extract
showed no significant antiproliferative bioactivity on
four of the five cancer cell lines tested (Figure 1), whilst
the methanol extract was only significantly effective
against two of the five cancer cell lines. In contrast, the
hexane extract, and thus the low polarity compounds,
were the most affective, showing a strong antiprolifera-
tive affect on all five cancer cell lines above that seen on
the two control cell lines (Figure 1).
Further enrichment of the antiproliferation active
compounds from the hexane-partitioned fraction by
quick column chromatography
Given that the hexane partitioned fraction showed the
greatest antiproliferative effect on the five tested cancer
cell lines (Figure 1), it was selected for further enrich-
ment by quick column chromatography. The eight frac-
tions obtained from the different elution solvent
mixtures revealed seven different appearances (70DCM
Table 1 Preferential cytotoxicity (IC50 value in μg/ml) of
ethanol crude extract on five cancer cell lines and two
normal cells
Cancer cell lines Normal cells
BT474 Chago SW620 Hep-G2 KATO-III HS27 CH-liver
20.40 31.67 19.88 36.19 22.98 37.85 29.14






Hexane Low Light brown and sticky liquid
CH2Cl2 Medium Dark brown and sticky solid
40% (v/v)
MeOH
High Very dark brown to black solid
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and 100DCM were similar) (Table 3), but the highest
polarity fraction, obtained from elution with 1:9 (v/v)
ratio of methanol: CH2Cl2 revealed essentially no anti-
proliferative activity (Figure 2). In contrast, based on the
IC50 (μg/ml) values, the fraction obtained from the 1:9
(v/v) ratio of CH2Cl2: hexane revealed a general antipro-
liferative effect and was not specific to the cancer cell
lines. The pure hexane eluted fraction revealed a low
cytotoxicity to the control CH-liver cells and a high
cytotoxicity on four of the cancer cell lines, the excep-
tion being the Chago cell line (66.9 μg/ml compared to
66.2 μg/ml for the control CH-liver cell line). In con-
trast, the fractions eluted from the 3:9, 1:1 and 7:3 (v/v)
ratios of CH2Cl2: hexane revealed a significant antiproli-
feration activity on all five cancer cell lines but only a
slight affect on the control CH-liver cell line. From
these three fractions that which eluted from the 3:7 (v/
v) ratio of CH2Cl2: hexane (30DCM) was selected for
further enrichment by size exclusion chromatography.
In addition, the fraction that eluted in pure CH2Cl2
(100DCM) was selected for further enrichment.
Although the 100DCM extract displayed a high antipro-
liferation activity on the control normal cell lines, it dis-
played a very high activity against all five cancer cell
lines, and so was selected in case the two activities
could be segregated by further enrichment.
Further enrichment of the active compounds by size
exclusion chromatography
As mentioned above, fractions 30DCM and 100DCM
were the most active in the MTT based in vitro antipro-
liferation of cancer cell lines, and so were selected for
size exclusion chromatography. For both 30DCM and
100DCM, after size exclusion chromatography, four
positive fractions (F1 - F4) were obtained with varying
appearances (Table 4). Comparing the color of these
fractions after size exclusion chromatography to the
color of crude extract in table 2, a lighter color was evi-
dent after size fractionation.
Figure 1 Average in vitro IC50 values (μg/ml) of the three
different solvent partitioned fractions (see Table 2) on the five
cancer and two normal cell lines in tissue culture, as
determined by the MTT assay. Hex = hexane extract, DCM =
CH2Cl2 extract and MeOH = methanol extract. Data came from the
mean ± 1 SD of percentage of cell viability which was derived from
three replicates.
Table 3 Eight compounds purified by quick column
chromatography
Purified compounds Characteristics
100HEX yellow and green, sticky liquid
10DCM transparent, light yellow and brown, sticky liquid
30DCM transparent, light brown and sticky solid
50DCM transparent, like 30DCM but lightly darker
70DCM transparent, dark brown and sticky solid
100DCM transparent, dark brown and sticky solid
5MET brown and black solid
10MET light yellow solid
Figure 2 Average IC50 (μg/ml) values of the eight fractions,
obtained after quick column chromatography, on the five
cancer and two normal cell lines. 100HEX, 10DCM, 30DCM,
50DCM, 70DCM, 100DCM, 5MET and 10MET stand for the fractions
eluted in 0:1, 1:9, 3:7, 1:1, 7:3 and 1:0 (v/v) ratios of CH2Cl2: hexane,
and 1:19 and 1:9 (v/v) ratios of MeOH: CH2Cl2, respectively (see table
3). Data came from the mean ± 1 SD of percentage of cell viability
which was derived from three replicates.




30DCM-F2 Yellowish brown solid
30DCM-F3 Brown solid
30DCM-F4 Yellow solid
100DCM-F1 Reddish brown solid
100DCM-F2 Brown solid
100DCM-F3 Yellowish brown solid
100DCM-F4 Brown solid
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These eight fractions (Table 4) revealed different
antiproliferation activities on the five cancer cell lines
as well as the control cell lines (Table 5). Fractions 1
and 4 from the 30DCM extract revealed no detectable
activity on all tested cell lines, whilst fractions 1 and 2
from the 100DCM fraction showed only a weak activ-
ity against one or all, respectively, of the five cancer
cell lines. Fractions 3 and 4 from the 100DCM extract
were among the three most active fractions, but also
showed a strong inhibition of the control cell lines.
Thus, the antiproliferative affect of the 100DCM frac-
tion on the cancer and normal cell lines was not segre-
gated. In contrast, fractions 2 and 3 from the 30DCM
extract showed a moderately and very strong antiproli-
ferative affect on all five cancer cell lines but not the
control cell lines (Table 5).
Discussion
In this research, initial purification steps were performed
on the propolis in order to enrich for the selective anti-
proliferative bioactive fraction, using a cell line antiproli-
feration assay as a guide. Ethanol was used as the
extraction solvent to provide a crude propolis extract as
discussed in Orsolic et al. [24]. In addition, Sawaya et
al. reported that the soluble compounds could be easily
released from the sticky part of propolis by a high per-
centage of alcohol [25]. Considering the crude ethanol
extract of T. laeviceps propolis, not only was a cytotoxic
affect on the five selected cancer cell lines seen but also
on the two control normal cell types. The IC50 (μg/ml)
between the inhibition of cancer and control cell line
proliferation were close (Table 1), preventing useful
anti-cancer application. A similar result has been
observed in the crude aqueous extract of propolis from
A. mellifera in Iran, where although it could inhibit the
in vitro growth of some cancer cell lines, it could also
stimulate the growth of normal cells [23]. Because there
might be compounding effects due to the potential pre-
sence of catatonic agents at high bioactive
concentrations mixed in with the desired bioactivity
compounds, we further enriched the fractions.
Solvent partitioning based upon different solvent pola-
rities was used for further purification and the antiproli-
feration active compounds were likely to be non-polar
or low polar chemicals since the high cytotoxicity was
principally observed in the hexane partitioned fraction
(Figure 1). This agrees with Marcucci et al. who
reported that the main chemical components in propolis
were phenolic compounds of a low polarity [26]. Con-
sidering the physical appearance of the hexane-parti-
tioned fraction, which was a light brown sticky liquid
(Table 2), this contrasts to the crude ethanolic extract of
the propolis as a rather dark solid. The change of
extract characters after solvent partition based enrich-
ment may represent the removal of some resin and wax
from the original propolis. The difference in the
observed IC50 (μg/ml) values for the antiproliferation
activity between the five cancer cell lines (< 25) and the
two normal cell lines (> 30) was evident (Figure 1), but
not different enough to likely be clinically useful. Thus,
the hexane-partitioned fraction was then further fractio-
nated by quick column chromatography with elution
based upon solvents of increasing polarity. In terms of
the IC50 values for antiproliferation activity, the 30DCM
fraction was the one of the most active fractions against
the five cancer cell lines but uniquely showed in con-
trast a very poor activity against the two normal (con-
trol) cell lines, and thus showed a good selective
antiproliferation activity. That it eluted from a 3:7 (v/v)
ratio of CH2Cl2: hexane is still consistent with the
notion that the active compounds are of low polarity.
The physical appearance of the 30DCM fraction as a
brown solid (Table 3) again supported the removal of
other components including resin and wax. Regardless,
the IC50 (μg/ml) value for the CH-liver control cell line
was increased, whilst that for the five cancer cell lines
was significantly decreased (Figure 2), although the var-
iation in response between the cell lines was marked.
The further enrichment of fraction 30DCM by size
exclusion chromatography yielded one fraction,
30DCM-F3, which provided the highest cytotoxicity on
cancer cell lines but the lowest cytotoxicity on normal
cells (Table 5).
Furthermore, considering the TLC separation pattern,
the more purification steps that were performed the bet-
ter the observed separation and migration of com-
pounds was (data not shown). Overall, the bioassay-
guided isolation would appear to be suitable to use in
order to obtain the purified active compounds (Figure
3), as reported before [18], but the other fractions need
to be screened as well, and the fractions processed to
pure compounds for confirmation. However, considering
the results presented here, it is possible that the
Table 5 Preferential cytotoxicity (IC50 value in μg/ml) of
positive fractions after size exclusion chromatography on
five cancer cell lines and two normal cells
Fraction Cancer cell lines Normal cells
BT474 Chago SW620 Hep-G2 Kato-III CH-liver
30DCM-F1 >100 >100 >100 >100 >100 >100
30DCM-F2 18.70 48.64 27.84 13.5 18.07 57.77
30DCM-F3 9.50 14.67 9.20 10.93 4.09 80.15
30DCM-F4 >100 >100 >100 >100 >100 >100
100DCM-F1 73.70 >100 52.72 62.53 58.88 57.73
100DCM-F2 70.91 >100 >100 >100 67.85 >100
100DCM-F3 7.64 16.7 14.28 15.98 7.55 19.35
100DCM-F4 9.34 11.37 7.98 9.64 8.31 9.93
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antiproliferation activity in each or some of the fractions
is derived from a combination of compounds. Certainly,
Orsolic et al. reported a synergistic antitumor effect by
the water-soluble derivatives of propolis from A. melli-
fera in Croatia [27]. In the future, the fractional inhibi-
tory concentration index (FICI) method should be
performed in order to determine the level, if any, of
synergy and antagonism. In addition, the purification to
homogeneity and analysis of the chemical structures of
each bioactive component should be performed in order
to investigate which exact compounds in Thai propolis
are responsible for the antiproliferation, and to act as
the template for future drug design.
Conclusions
Propolis of the stingless bee (Trigona laeviceps) from
Thailand was tested for antiproliferative activity. Five
cancer cell lines (Chago, Kato-III, SW620, BT474 and
Hep-G2) and two normal cell lines (CH-liver cells and
HS27 fibroblast cells) were selected for this purpose.
The crude ethanolic extract displayed a good antiprol-
ferative activity. For example, the IC50 was 19.9 and 29.1
μg/ml for the SW620 cancer cell line and CH-liver cells,
respectively. After solvent partitioning, the hexane frac-
tions revealed the highest antiproliferative activity
against the five cancer cell lines and the lowest cytotoxic
activity on the normal cell lines. For example, IC50
values of 16.4 and 32.4 μg/ml for the SW620 cancer cell
line and CH-liver cells, respectively. The hexane fraction
part was, therefore, purified in the next step by quick
column and size exclusion chromatography. Considering
the IC50, it was obvious that the more purified fractions
were, the higher the antiproliferative activity was
achieved. Two fractions that eluted with 30% and 100%
(v/v) CH2Cl2 in hexane (30DCM and 100DCM, respec-
tively) are potential sources of new antiproliferative
compounds. Thus, T. laeviceps propolis from Thailand
contains some bioactive compounds that are not only
effective in antiproliferative activity on cancer cell lines,
but also nontoxic to normal cell lines. In the future, it is
possible that the bioactive compounds could serve as a
template for anticancer-drug developing program.
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